# Castle Biosciences (CSTL) — Earnings

CSTL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cstl/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.07 |
| EPS estimate | −$0.41 |
| EPS surprise | +82.81% |
| Revenue surprise | +20.07% |
| Revenue | $103.5M |
| Revenue estimate | $86.2M |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1447362/000162828026051052/cstl-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/beb23b58-b4b2-776a-743d-b7da2cf19b2d.html) |

Castle Biosciences reported Q2 2026 results on July 30, 2026, posting a loss of $0.07 per share. Analysts expected a $0.41 loss, so the result beat by 82.81%. Revenue of $103.5 million topped the $86.2 million consensus by 20.07% and is the highest quarter in the table. Against Q2 2025, revenue rose about 20% from $86.2 million, but EPS moved from a $0.15 profit to a loss.

Revenue has grown much faster than earnings. Annual revenue rose from $137.0 million in 2022 to $343.4 million in 2025, about two and a half times as much. Castle beat the revenue estimate in all 20 quarters shown. EPS has been mostly negative: losses of $2.58 per share in 2022 and $2.16 in 2023, a $0.62 profit in 2024 and a $0.85 loss in 2025. Only four quarters were profitable, Q2 through Q4 2024 and Q2 2025. The first half of 2026 totals a loss of $0.56, narrower than $0.75 a year earlier.

Q3 results arrived between November 2 and November 8 in each of the past five years. That points to early November 2026, when the report will show whether revenue stays above $100 million and whether the loss narrows further.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | −$0.41 | −$0.07 | 82.81% | $86.2M | $103.5M |
| Q1 2026 | May 6, 2026 | −$0.49 | −$0.49 | 0.00% | $79.2M | $84.2M |
| Q4 2025 | Feb 26, 2026 | −$0.26 | −$0.08 | 69.06% | $79.9M | $87.0M |
| Q3 2025 | Nov 3, 2025 | −$0.52 | −$0.02 | 96.16% | $71.1M | $83.0M |
| Q2 2025 | Aug 4, 2025 | −$0.53 | $0.15 | 128.24% | $71.4M | $86.2M |
| Q1 2025 | May 5, 2025 | −$0.07 | −$0.90 | -1196.83% | $80.3M | $87.2M |
| Q4 2024 | Feb 27, 2025 | $0.05 | $0.32 | 579.41% | $81.9M | $85.8M |
| Q3 2024 | Nov 4, 2024 | −$0.00 | $0.08 | 2100.00% | $79.9M | $85.8M |
| Q2 2024 | Aug 5, 2024 | −$0.27 | $0.31 | 215.37% | $69.4M | $86.6M |
| Q1 2024 | May 2, 2024 | −$0.33 | −$0.09 | 72.89% | $66.5M | $71.3M |
| Q4 2023 | Feb 28, 2024 | −$0.56 | −$0.10 | 82.22% | $56.3M | $66.1M |
| Q3 2023 | Nov 2, 2023 | −$0.76 | −$0.26 | 65.97% | $48.6M | $60.6M |
| Q2 2023 | Aug 2, 2023 | −$0.92 | −$0.70 | 23.51% | $44.2M | $50.2M |
| Q1 2023 | May 3, 2023 | −$0.89 | −$1.10 | -23.53% | $37.4M | $43.4M |
| Q4 2022 | Feb 28, 2023 | −$0.84 | −$0.78 | 6.88% | $37.1M | $38.3M |
| Q3 2022 | Nov 2, 2022 | −$0.88 | −$0.77 | 12.56% | $34.8M | $37.0M |
| Q2 2022 | Aug 8, 2022 | −$0.76 | −$0.06 | 92.12% | $28.4M | $34.8M |
| Q1 2022 | May 9, 2022 | −$0.71 | −$0.97 | -37.18% | $25.2M | $26.9M |
| Q4 2021 | Feb 28, 2022 | −$0.47 | −$0.25 | 46.87% | $23.7M | $25.0M |
| Q3 2021 | Nov 8, 2021 | −$0.41 | −$0.47 | -16.05% | $23.0M | $23.5M |

## Frequently Asked Questions

### When did Castle Biosciences (CSTL) last report earnings?

Castle Biosciences last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did CSTL beat earnings estimates?

Yes. Castle Biosciences reported EPS of −$0.07 for Q2 2026 against a −$0.41 estimate — a 82.81% beat.

### How much revenue did CSTL report last quarter?

Castle Biosciences reported $103.5M in revenue for Q2 2026, against a consensus estimate of $86.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).